Table 1.
Univariate analysis of factors associated with discordant HIV-1 RNA levels in paired CSF and plasma samples
| CSF/plasma discordance | p value | ||
|---|---|---|---|
| Yes (n = 20) | No (n = 133) | ||
| Age, median years (IQR) | 46 (43, 50) | 46 (41, 54) | 0.913 |
| Gender male, n (%) | 15 (75) | 117 (88) | 0.156 |
| Risk group/ethnicity, n (%) | 0.007 | ||
| White MSM | 7 (35) | 80 (60) | |
| Black heterosexual | 8 (40) | 17 (13) | |
| Other | 5 (25) | 36 (27) | |
| CD4, median cells/mm3 (IQR) | |||
| Nadir | 32 (21, 256) | 159 (49, 281) | 0.030 |
| Current | 374 (190, 613) | 464 (310, 707) | 0.163 |
| Years since HIV diagnosis, median (IQR) | 10 (7, 16) | 9 (5, 16) | 0.833 |
| ART at sampling, n (%) | 0.178 | ||
| PI/r based | 14 (70) | 74 (55) | |
| NNRTI based | 3 (15) | 47 (35) | |
| Other | 3 (15) | 12 (9) | |
| CPE, median (IQR) | 7 (7, 10) | 7 (6, 8) | 0.250 |
| Self reported adherence <95 %, n (%) | 2 (10) | 12 (9) | 1.000 |
| CSF WCC median cells/mm3 (IQR) | 11 (<1, 21) | <1 (<1, 3) | 0.018 |
| CNS infection, n (%) | 3 (15) | 18 (14) | 0.740 |
Risk group and ethnicity were combined due to co-linearity; 89 % of MSM were white. CSF white cell count was tested in 24 (60 %) of LLV patients and all patients in the clinical cohort
MSM men who have sex with men, IVDU intravenous drug user, IQR interquartile range, PI/r ritonavir-boosted protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside/tide reverse transcriptase inhibitor, RAL raltegravir, MVC maraviroc, CPE CNS penetration effectiveness score 2010